HLX53

HLX53 is an anti-TIGIT Fc fusion protein independently developed by Henlius. It consists of the variable domain of a heavy chain of a heavy-chain antibody (VHH) fused to a wildtype IgG1 Fc region. As an immune checkpoint inhibitor targeting T cell immunoglobulin and ITIM domains (TIGIT), HLX53 is designed to block the inhibitory signals mediated by TIGIT, which is expressed on natural killer (NK) cells, activated CD8+ and CD4+ T cells, and regulatory T cells. By inhibiting TIGIT's interaction with its ligand CD155 on antigen-presenting or tumor cells, HLX53 aims to restore antitumor immune responses that are otherwise suppressed in the tumor microenvironment. Preclinical studies have shown that HLX53 exhibits strong tumor inhibition with good safety profiles. The drug is being developed primarily for advanced or metastatic solid tumors—including hepatocellular carcinoma—and lymphomas[1][2][3][4][5].

Other names

anti-TIGIT Fc fusion protein